Veracyte touts results of Percepta genomic sequencing study

By staff writers

January 25, 2022 -- Veracyte has released data from a study that used the company's Percepta genomic sequencing classifier (GSC), which the company reported can deliver curative therapy for patients with high-risk lung nodules and inconclusive bronchoscopy results.

The study was published January 6 in BMC Pulmonary Medicine. Researchers looked at data from 101 survey respondents who provided a total of 1,341 evaluations of 37 patient cases across three different cohorts.

They found that the rate of recommendation for surgical resection was significantly higher in the independent cohort with a GSC result at 45% compared to the independent cohort without a GSC result at 17% (p < 0.001). They also found that in the pre-post crossover cohort, the rate increased from 17% to 56% (p < 0.001) following the review of the GSC result.

Veracyte also said the study showed that the test can increase physician confidence in clinical decision-making and lead to fewer unnecessary diagnostic procedures.

Veracyte touts results of Decipher classifier study
Veracyte shared data from a study touting the success of its Decipher Prostate Biopsy genomic classifier in helping guide treatment decisions for prostate...
Veracyte taps new executive vice president, CFO
Global genomic diagnostics firm Veracyte has appointed Rebecca Chambers as its new executive vice president and chief financial officer (CFO). Her tenure...
Veracyte inks deal to purchase HalioDx
In a bid to expand its cancer diagnostics presence, Veracyte has signed an agreement to acquire immuno-oncology testing company HalioDx. The deal is expected...
Veracyte to highlight Decipher clinical data at ASCO
Veracyte plans to highlight results at the virtual American Society of Clinical Oncology (ASCO) from two studies that show its Decipher prostate genomic...
Veracyte completes Decipher acquisition for $600M
Veracyte has completed a $600 million cash deal to acquire Decipher Biosciences, expanding its position in the genomics-driven cancer diagnostics...

Copyright © 2022

Last Updated bc 1/25/2022 8:07:17 PM